Back to All

Asuragen and Labceutics Report Results from Pan European Quality Assurance-Modeled Study on Standardization of BCR-ABL1 Monitoring for CML Patients

4 September, 2014

Asuragen Labceutics, a leader in molecular diagnostics, has released the results of its Pan-European Quality Assessment Program. The program aims to assess the quality of molecular diagnostic testing across Europe, ensuring consistency and accuracy in patient care.

Through this initiative, Asuragen Labceutics provides valuable insights into the performance of molecular diagnostic laboratories, highlighting areas of excellence and opportunities for improvement. By promoting standardized practices and quality assurance measures, the program contributes to the advancement of molecular diagnostics and enhances patient outcomes.

Explore the full article to learn more about Asuragen Labceutics' commitment to quality and innovation in molecular diagnostics across Europe.

Click here to view the full article

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane

Tel: +44 (0)20 3405 0205 or [email protected]

Caroline Forde
Robyn Fisher
Kieran Breheny